Specific lipids in tumours linked to cancer progression and patient survival

NewsGuard 100/100 Score

Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many cancers. However, the precise molecular composition of lipids in tumours remains generally poorly characterised. Scientists from VTT Technical Research Centre of Finland and the Charité Hospital have found lipids in tumours which are associated with cancer progression.

A new study performed by Matej Orešič and colleagues from the VTT Technical Research Centre of Finland in collaboration with the team of Carsten Denkert (Institute of Pathology, Charité Hospital, Berlin, Germany) in the European consortium METAcancer reveals specific lipids found in tumours associated with cancer progression and patient survival. These findings, which were published in Cancer Research, might be an important step towards the development of personalised cancer therapeutics.

The team used lipidomics, a high-throughput method for detecting molecular lipids, to analyse a large number of breast tumour tissues. Specific phospholipids related to cellular fatty acid synthesis were associated with cancer progression and patient survival. Follow-up in vitro studies, including gene silencing, identified several lipid metabolism genes behind the observed lipid changes in tumours.

The findings imply that phospholipids may have diagnostic potential, and that modulation of their metabolism may provide new therapeutic opportunities in breast cancer treatment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Lancet Commission on Breast Cancer: Transforming breast cancer care globally